Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 26.8% - Should You Sell?

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) dropped 26.8% on Monday . The company traded as low as $0.42 and last traded at $0.45. Approximately 86,930,683 shares were traded during trading, an increase of 196% from the average daily volume of 29,385,932 shares. The stock had previously closed at $0.61.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research note on Monday. They set a "hold" rating for the company.

Tonix Pharmaceuticals Price Performance

The stock has a 50 day moving average of $0.21 and a 200-day moving average of $0.41. The stock has a market capitalization of $75.34 million, a P/E ratio of -0.01 and a beta of 2.23. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $1.80. The business had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. On average, equities research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.